U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07587814) titled 'Impact of Body Composition on Dosimetry of 177Lu-PSMA Radioligand Therapy' on April 20.
Brief Summary: COCORIVO is an interventional study evaluating the impact of body composition on dosimetry of 177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Body composition (muscle, lean, visceral fat, subcutaneous fat and total fat masses) will be automatically quantified from whole-body CT images acquired at 72-96h after 177Lu-PSMA injection using the Anthropometer3DNet software. Dosimetry will be evaluated for tumors and organs at risk (salivary glands, bone marrow, kidneys). The study a...